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Ten years ago, a group of scientists published the roadmap Seeding the
EuroPhysiome: A Roadmap to the Virtual Physiological Human (STEP, http://www.
vph-institute.org/upload/step-vph-roadmap-printed-3_5192459539f3c.pdf). This
triggered a major investment in research in the virtual physiological human
(VPH). The VPH was defined as a ‘methodological and technological framework
that, once established, will enable collaborative investigation of the human body
as a single complex system.’ The roadmap also stipulated that ‘VPH is not
‘the supermodel’ that will explain all possible aspects of human physiology or
pathology. It is a way to share observations, to derive predictive hypotheses from
them, and to integrate them into a constantly improving understanding of
human physiology and pathology, by regarding it as a single system.’
Even earlier, 10 years before thepublicationof theSTEProadmapand following
the 33rd IUPS World Congress in St Petersburg in 1997, the Physiome committee
was established, which had the ambitious goal to provide computational
frameworks for integrative multiscale modelling and simulations of human physi-
ology, including reproducible, reusable and modular components that would
enable the creation of complex multiscale models of human health and disease.
We may conclude that the STEP consortium adeptly sensed the wave of
technological innovations that were about to happen and that VPH researchers
and engineers have used to their full advantage to push forward the VPH.
Today, we live in a fully connected world, with an abundance of available
(medical) data that can be accessed via dedicated interfaces and analysed
with workflows that can execute in seemingly unbounded cloud computing
resources. Individuals have unprecedented opportunities to instrument them-
selves with, for instance, smart watches, and instantaneously share data on
their own physiology with the rest of the world. And many people actually do
that! Within healthcare and in the clinical setting, these technological advance-
ments have a strong impact that in combination with ever-improving medical
technology will lead to further improved and more personalized medicine.
The VPH/Physiome has become a mature and flourishing scientific
community. Research in the VPH/Physiome contributes to many aspects of com-
putational biomedicine, ranging from developing descriptive complex multiscale
models for deeper understanding of human physiology and pathophysiology
and their related (simulation) technologies, to patient-specific models and their
related (IT) technologies, with clinical relevance for applications in diagnosis
and treatment prediction [1]. And, as Viceconti and Hunter write, ‘in 2011 the
vision of the VPHwas fully developed’, with threemain targets for VPH research:
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forecasting (VPH for the patient/citizen) [1].
Currently, the VPH is a worldwide effort to integrate all
information available, from genetics to medical images to
clinical data, for each patient, and generate computer models
capable of predicting how the health of that patient will
evolve under certain conditions or after personalized treat-
ment. VPH strongly contributes to improving healthcare,
well-being and healthy ageing. VPH has seen tremendous
scientific development and impact, as for example, witnessed
in previous special issues, also in this journal [2–11].
In September 2016, the biannual Virtual Physiological
Human Conference was held at the Royal Tropical Institute in
Amsterdam, The Netherlands (http://2016.vph-conference.
org). The conference was organized by the Virtual Physiologi-
cal Human Institute (http://www.vph-institute.org) and was
the fourth in a row, starting in 2010 in Brussels, Belgium,
then in London, UK, in 2012 and in Trondheim, Norway, in
2014. The next VPH conference is currently being organized
and will be held in Zaragoza, Spain, in September 2018.
The theme of the VPH2016 conference was ‘translating
VPH to the clinic’. We have already seen some examples of
VPH applications that have been applied, or are close to
being applied, in clinical settings [1]. The first VPH model to
receive full FDA approval was virtual Fractional Flow Reserve
based on computed tomographic angiography. Moreover, a
phase 1 clinical trial for virtual Fractional Flow Reserve using
rotational coronary angiography was recently completed.
VPH models for accurate differential diagnosis of pulmonary
hypertension also recently completed a phase 1 clinical trial.
VPH technologies for planning transcatheter aortic valve
implantation and paediatric percutaneous pulmonary valve
implantation have been demonstrated, as well as for predicting
the risk of bone fracture in osteoporotic patients [1].
We have selected eight contributions to the VPH2016 con-
ference that not only cover new ground in computational
biomedicine, but also contribute towards clinical appli-
cations. These papers demonstrate how many years of VPH
research can now (potentially) lead to real clinical appli-
cations. Five of these papers show examples of personalized
digital patient models, two papers address pathologies
studied in virtual populations, and finally one paper is on a
multiscale modelling framework for the VPH.1
The most advanced VPH applications close to, or currently
used in, clinical practice are in the field of cardiovascular
disease, e.g. the already mentioned virtual Fractional Flow
Reserve. A major issue in personalizing such haemodynamic
predictions is choosing correct patient-specific boundary
conditions, and for some applications also patient-specific
mechanical properties of the arterial wall. Itu et al. [12] propose
a procedure for personalizing aortic haemodynamic compu-
tations from four-dimensional magnetic resonance imaging
data, which they successfully evaluate on 15 datasets from
patients with aortic valve disease. An example of an application
that requires such personalizedmodels is the planning of medi-
cal procedures in cardiovascular disease. Capelli et al. [13] report
on their experience with a modelling framework for patient-
specific prediction of clinical outcomes. They apply their
models to three procedures in relation to congenital heart dis-
ease (percutaneous pulmonary valve implantation, stenting of
aortic coarctation and surgical repair of double outlet right ven-
tricle) and they include 12 patients in their study. They
demonstrate good agreement between simulations and clinicaldecisions (such as device choice), and they argue that their
studysupports translationof suchVPHtools forpersonalization
of cardiovascular treatments. The limited number of patients in
both studies underscores the preliminary nature of these find-
ings. However, the results show the way forward and seem to
warrant evaluation studies of larger patient cohorts.
Predicting the outcome of treatment for decision support is
also addressedbyOuzounoglou et al. [14]who apply theironco-
simulator to simulate progression and response to the treatment
of acute lymphoblastic leukaemia (ALL). Themechanistic simu-
lator is combined with optimization and machine learning
methods for parametrization of the model, based on data from
a cohort of 191 patients. The resultingHybridALLOncosimula-
tor is then applied to predict the prednisone response category
of a newly arrived ALL patients, with correct classification for
around 70% of patients. The authors discuss how this could
be elevated to 95% and how the simulator could be applied to
longer and more complex treatments.
Prediction of risk factors, such as risk of rupture of cerebral
aneurysms [1], is another potential use case for VPHmodels in
clinical practice, again in decision support scenarios. Akyildiz
et al. [15] study atherosclerotic plaque rupture, which is the
primary cause of cardiac and cerebral ischaemic events. Accu-
rate rupture risk stratification of atherosclerotic plaques is
important for planning preventive treatment strategies. High
structural plaque stresses strongly correlate with plaque rup-
ture. Using dedicated heterogeneous finite-element models,
Akyildiz et al. compute peak cap stresses on atherosclerotic
plaques from 12 atherosclerotic human coronaries, and study
the sensitivity of this stress in relation to plaque structure.
For the first time, heterogeneity of plaque structure was
considered to compute the peak cap stresses.
An example of using VPHmodels in prospective studies, to
support analysis and shed light on emerging hypotheses, is pro-
vided by Guo et al. [16], who use personalized modelling of
fluid transport in the brain to help decipher underlying mech-
anisms regarding Alzheimer’s disease. Using subject-specific
data from 103 individuals as input for an extended model of
perfused parenchymal tissue coupled to subject-specific
meshes, permeability tensor maps and cerebral blood flow,
the authors aim to build an understanding of the exact nature
of emerging evidence, suggesting that Alzheimer’s disease is
a vascular disorder, caused by impaired cerebral perfusion,
which in turn may be promoted by cardiovascular risk factors
that are strongly influenced by lifestyle. This paper describes
in some detail the underlying models and ways to personalize
them, and discusses two specific patient cases.
Virtual populations are computer models of real popu-
lations, to which VPH models can then be applied to study
phenomena on the cohort level. Such virtual populations or vir-
tual cohorts will be used in, for instance, in silico clinical trials
[1], and with the recent start of a new wave of EU-funded pro-
jects fully dedicated to in silico clinical trials, we may expect to
see new results with immediate relevance for healthcare and
clinical practice. The paper by Clemmer et al. [17] provides an
exciting example of what we can expect from modelling with
virtual populations. These authors use the Humod model, an
extended mathematical model of human physiology, to create
a heterogeneous virtual population of 1000 virtual patients by
randomly varying physiological parameters in the model, and
then investigate mechanisms responsible for the change in
blood pressure in response to a high-salt diet, both with full
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able to distinguish five clusters of salt-sensitive individuals.
Such population modelling can also contribute to reducing
the use of animals in preclinical studies prior to any transla-
tional studies in human volunteers. Laranjeira et al. [18]
study anti-inflammatory treatment with chemerin to find
new and safer drugs in routine treatment of mild-to-moderate
chronic pain. A mouse model showed the inhibitory effect of
chemerin on recruitment of inflammatory cells. The next step
is to evaluate the therapeutic potential of optimized protocols
for drug concentration and timing of injection. Instead of sacri-
ficing a large number of laboratory animals to do an exhaustive
search, Laranjeira et al. use available mouse data to develop
and parametrize a mathematical model, which is subsequently
used to optimize the therapeutic potential of chemerin.
Finally, to stipulate that although a major goal of the
VPH/Physiome is translation to clinical applications, there
is strong ongoing research in the underpinning modelling
and simulation paradigms and related standardization
initiatives, without which it would be very difficult to deliver
integrated multiscale models of complex physiology for digi-
tal patient modelling, de Bono et al. [19] show how to
represent biophysical processes between and within modular
biological compartments. They propose a new framework for
developing multiscale biophysical models in physiology by
combining ApiNATOMY, a representation of functional anat-
omy, with Bond Graphs, an engineering methodology that
represents mass- and energy-conserving processes consist-
ently, and demonstrate its capabilities by linking models for
blood and urine flow in the kidney with biochemical anddiffusive processes between blood and urine of the proximal
tubule in the nephron, and finally with membrane transporters
in the renal tubular epithelium.
VPH2016 was a very successful conference, and this
special issue catches some of the excitement during the con-
ference. As a community, the VPH/Physiome has made
tremendous progress, but the biggest challenges still lie
ahead of us. We are on a road of creating our ‘digital
twins’, to be used in clinical digital patient settings when
we are ill, or in personal health forecasting to support us in
adopting and maintaining a healthy lifestyle, or as part of a
virtual population to be applied for in silico trials. This
requires extension of not only fundamental research, but
even more so of translational research of the type that is
described in this special issue. In addition, successful
implementation of these efforts also requires strong engage-
ment of EMA and FDA, and solid connections with the
medical device and pharma industry, as is currently happen-
ing with the help of the VPH institute and the Avicenna
Alliance (http://avicenna-alliance.com).
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